ReviewDrugs in context2022
Dermatology: how to manage acne in skin of colour.
Review in Drugs in context, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Treatment of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review.Journal of cutaneous medicine and surgeryPooled it
- Expert Consensus on the Rational Approach to Isotretinoin Usage for Effective Management of Acne: ERAISE ACNE Recommendations.Dermatology and therapy · 2026Review
- Paving the Way to Healthcare Equity: A Comprehensive Review of Care Gaps and Emerging Initiatives in Dermatology.Dermatology and therapy · 2026Review
- The Role of Dermocosmetics in Acne Management: Asian Perspective.Clinical, cosmetic and investigational dermatology · 2026Article
- Efficacy and Safety of Sarecycline in Chinese Patients with Moderate-to-Severe Acne Vulgaris: Randomized Phase 3 Clinical Trial with Open-Label Follow-Up.Dermatology and therapy · 2025Article
- Investigating demographic differences in women's dermatologic concerns: a large urban cohort study.International journal of women's dermatology · 2025Article
- PRACT-India: Practical Recommendations on Acne Care and Medical Treatment in India-A Modified Delphi Consensus.Antibiotics (Basel, Switzerland) · 2025Article
- Acne-induced Post-inflammatory Hyperpigmentation: From Grading to Treatment.Acta dermato-venereologica · 2025Review
- CaSMO Recommendations for Prevention and Treatment of Cutaneous Adverse Events Related to Cancer Therapies in Darker Skin Phototypes.Clinical, cosmetic and investigational dermatology · 2025Article
- Is Acne the Same Around the World?The Journal of clinical and aesthetic dermatology · 2024Review
- Efficacy of Glycyrrhetinic Acid in the Treatment of Acne Vulgaris Based on Network Pharmacology and Experimental Validation.Molecules (Basel, Switzerland) · 2024Article
- Managing acne vulgaris: an update.Drug and therapeutics bulletin · 2023Review
- Human Skin Pigmentation: From a Biological Feature to a Social Determinant.Healthcare (Basel, Switzerland) · 2023Review
- A Post Hoc Analysis of Efficacy Data on Sarecycline in Hispanics with Acne from Two Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trials.Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acne vulgaris is a prevalent dermatological condition worldwide but is especially challenging to treat in individuals with skin of colour (SOC). Corresponding to Fitzpatrick skin phototypes III-VI, people of African, Asian, Middle Eastern and Hispanic ethnicity are considered to have SOC. With the additional risk of postinflammatory hyperpigmentation (PIH) as a consequence of inflammatory acne or its respective treatment, managing acne in this population holds significant importance. PIH adversely impacts self-esteem and quality of life and, thus, is usually the patient's priority of treatment. Available acne treatments are similar for all skin types. However, some are more beneficial for individuals with SOC, in particular by targeting both active acne lesions and PIH. The acne treatment literature was searched for topical and systemic treatments that were specifically studied in the SOC population. These treatments included topical agents, such as retinoids and azelaic acid, in addition to topical antibiotics and benzoyl peroxide. Newer formulations and combined regimens reported effective in reducing lesions are less likely to induce PIH and may treat pre-existing PIH. Moisturiser use, titrating doses and patient education are strategies to minimize irritation and improve adherence. In addition, systemic therapies, including oral antibiotics, isotretinoin, oral contraceptives and spironolactone, are efficacious for refractory acne or more severe cases but specific studies in SOC are lacking. Chemical peels may improve acne and target PIH directly. Overall, based on limited evidence, topical and systemic therapies are well tolerated in the SOC population but efficacy should be balanced with the risk of adverse effects. This narrative review aims to highlight formulations and combination therapies that are effective and safe for treating acne and PIH in patients with SOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.